These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 27055772)

  • 1. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
    Litim N; Morissette M; Di Paolo T
    Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
    Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
    Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia.
    Bennouar KE; Uberti MA; Melon C; Bacolod MD; Jimenez HN; Cajina M; Kerkerian-Le Goff L; Doller D; Gubellini P
    Neuropharmacology; 2013 Mar; 66():158-69. PubMed ID: 22491024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
    Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
    Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease.
    Duty S
    CNS Drugs; 2012 Dec; 26(12):1017-32. PubMed ID: 23114872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
    Niswender CM; Jones CK; Lin X; Bubser M; Thompson Gray A; Blobaum AL; Engers DW; Rodriguez AL; Loch MT; Daniels JS; Lindsley CW; Hopkins CR; Javitch JA; Conn PJ
    ACS Chem Neurosci; 2016 Sep; 7(9):1201-11. PubMed ID: 27441572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
    Maksymetz J; Moran SP; Conn PJ
    Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2017 Mar; 115():115-127. PubMed ID: 28216000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?
    Caraci F; Battaglia G; Sortino MA; Spampinato S; Molinaro G; Copani A; Nicoletti F; Bruno V
    Neurochem Int; 2012 Sep; 61(4):559-65. PubMed ID: 22306345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature.
    Lindsley CW; Hopkins CR
    Expert Opin Ther Pat; 2012 May; 22(5):461-81. PubMed ID: 22506633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
    Morin N; Morissette M; Grégoire L; Di Paolo T
    Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.
    Sengmany K; Singh J; Stewart GD; Conn PJ; Christopoulos A; Gregory KJ
    Neuropharmacology; 2017 Mar; 115():60-72. PubMed ID: 27392634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential.
    Goudet C; Vilar B; Courtiol T; Deltheil T; Bessiron T; Brabet I; Oueslati N; Rigault D; Bertrand HO; McLean H; Daniel H; Amalric M; Acher F; Pin JP
    FASEB J; 2012 Apr; 26(4):1682-93. PubMed ID: 22223752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
    Iderberg H; Maslava N; Thompson AD; Bubser M; Niswender CM; Hopkins CR; Lindsley CW; Conn PJ; Jones CK; Cenci MA
    Neuropharmacology; 2015 Aug; 95():121-9. PubMed ID: 25749357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
    Amalric M
    Curr Opin Pharmacol; 2015 Feb; 20():29-34. PubMed ID: 25462289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of allosteric modulation: Exploring the binding kinetics of glutamate and other orthosteric ligands of the metabotropic glutamate receptor 2.
    Doornbos MLJ; Vermond SC; Lavreysen H; Tresadern G; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2018 Sep; 155():356-365. PubMed ID: 30028996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives.
    Gasparini F; Kuhn R; Pin JP
    Curr Opin Pharmacol; 2002 Feb; 2(1):43-9. PubMed ID: 11786307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease.
    Lopez S; Bonito-Oliva A; Pallottino S; Acher F; Fisone G
    J Parkinsons Dis; 2011; 1(4):339-46. PubMed ID: 23939343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.
    Lundström L; Bissantz C; Beck J; Dellenbach M; Woltering TJ; Wichmann J; Gatti S
    Neuropharmacology; 2016 Dec; 111():253-265. PubMed ID: 27590915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials.
    Vallano A; Fernandez-Duenas V; Garcia-Negredo G; Quijada MA; Simon CP; Cuffí ML; Carbonell L; Sanchez S; Arnau JM; Ciruela F
    CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1128-42. PubMed ID: 24040811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.